IRINA KIBLITSKY: Open Payments
NPI 1215112719 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,974 in 162 payments from 21 companies in 2025. Trend: 2023 $2,617 · 2024 $4,478 · 2025 $4,974
Food & beverage: $4,754Education: $219
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $1,088 |
| Teva Pharmaceuticals USA, Inc. | 22 | $732 |
| ABBVIE INC. | 16 | $521 |
| Lundbeck LLC | 18 | $492 |
| Alkermes, Inc. | 13 | $370 |
| Vanda Pharmaceuticals Inc. | 13 | $290 |
| Neurocrine BioSciences, Inc. | 7 | $238 |
| Janssen Pharmaceuticals, Inc | 6 | $215 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $189 |
| Axsome Therapeutics, Inc. | 10 | $184 |
Products named: REXULTI, VRAYLAR, AUSTEDO XR, ABILIFY ASIMTUFII, LYBALVI, FANAPT, INGREZZA, CAPLYTA.
Industry payments across NY — which companies pay providers there.
